SOURCE: ViroCyt, Inc.

ViroCyt, Inc.

June 17, 2015 09:58 ET

ViroCyt Raises $4 Million in New Financing

BOULDER, CO--(Marketwired - June 17, 2015) - ViroCyt, the leader in rapid virus quantification, announced today that it has secured over $4 million in private investment.

The financing was led by a strategic investor with significant participation by existing shareholders. ViroCyt will use the capital to expand its global reach by adding new distributors in key markets, as well as to support the continued development of transformative products and applications.

"I'm excited to work with ViroCyt as they drive innovation for virus particle counting in the vaccine manufacturing, viral protein expression and gene therapy arenas," said Jack Ball, ViroCyt board member. "The ViroCyt technology is providing substantial cost- and time-savings across these industries."

ViroCyt's Virus Counter platform is being used to accelerate the development and production of life-saving vaccines and therapeutics at many of the world's top companies, regulatory agencies, government research institutes and universities. Examples include Sanofi Pasteur, Protein Sciences, GE Healthcare, FDA, NIAID and The University of Maryland.

The third generation of the Virus Counter, the 3100, was launched in 2014 with the primary goal of providing a system capable of withstanding the unique conditions in manufacturing settings. This includes increased stability, GMP compliance and the addition of an autosampler for walkaway processing of up to 96 samples per run.

"The funds from this financing will allow ViroCyt to continue to evolve our technology platform and product offerings in the expanding virus quantification market," stated Robert Kline, ViroCyt President and CEO. "We very much appreciate the support from our existing investor base and are encouraged by the participation from a major strategic in the biotech field."

About ViroCyt, Inc.

ViroCyt, Inc. was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. Additional information can be found at

Contact Information

  • Contact Information
    Dr. Michael Artinger
    Vice President, Marketing & Strategic Partnering
    ViroCyt, Incorporated
    Email contact